Lothar Germeroth
Overview
Explore the profile of Lothar Germeroth including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
384
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Manske K, Dressler L, Frassle S, Effenberger M, Tschulik C, Cletiu V, et al.
J Immunol Methods
. 2024 Jan;
526:113617.
PMID: 38215900
Immunotherapy using TCR and especially CAR transgenic T cells is a rapidly advancing field with the potential to become standard of care for the treatment of multiple diseases. While all...
2.
Fraessle S, Tschulik C, Effenberger M, Cletiu V, Gerget M, Schober K, et al.
Commun Biol
. 2023 Jun;
6(1):604.
PMID: 37277433
CAR T cell therapy is a rapidly growing area of oncological treatments having a potential of becoming standard care for multiple indications. Coincidently, CRISPR/Cas gene-editing technology is entering next-generation CAR...
3.
Radisch S, Poltorak M, Wagner M, Cletiu V, Radisch C, Treise I, et al.
Sci Rep
. 2022 Apr;
12(1):6572.
PMID: 35449227
Large-scale target cell isolation from patient blood preparations is one of the critical operations during drug product manufacturing for personalized cell therapy in immuno-oncology. Use of high-affinity murine antibody coated...
4.
Poltorak M, Graef P, Tschulik C, Wagner M, Cletiu V, Dreher S, et al.
Sci Rep
. 2020 Oct;
10(1):17832.
PMID: 33082362
T cell activation is a cornerstone in manufacturing of T cell-based therapies, and precise control over T cell activation is important in the development of the next generation T-cell based...
5.
Roex M, Hageman L, Veld S, van Egmond E, Hoogstraten C, Stemberger C, et al.
Blood
. 2020 Jun;
136(4):455-467.
PMID: 32483595
Tumor-associated antigens (TAAs) are monomorphic self-antigens that are proposed as targets for immunotherapeutic approaches to treat malignancies. We investigated whether T cells with sufficient avidity to recognize naturally overexpressed self-antigens...
6.
Roex M, van Balen P, Germeroth L, Hageman L, van Egmond E, Veld S, et al.
Leukemia
. 2019 Oct;
34(3):831-844.
PMID: 31624377
Prophylactic infusion of selected donor T cells can be an effective method to restore specific immunity after T-cell-depleted allogeneic stem cell transplantation (TCD-alloSCT). In this phase I/II study, we aimed...
7.
Roex M, Hageman L, Heemskerk M, Veld S, van Liempt E, Kester M, et al.
Cytotherapy
. 2018 Feb;
20(4):543-555.
PMID: 29449085
Background: Adoptive transfer of donor-derived T cells can be applied to improve immune reconstitution in immune-compromised patients after allogeneic stem cell transplantation. The separation of beneficial T cells from potentially...
8.
Tunger A, Wehner R, von Bonin M, Kuhn D, Heidenreich F, Matko S, et al.
Leuk Lymphoma
. 2016 Nov;
58(5):1246-1249.
PMID: 27852136
No abstract available.
9.
Nauerth M, Stemberger C, Mohr F, Weissbrich B, Schiemann M, Germeroth L, et al.
Cytometry A
. 2016 Aug;
89(9):816-25.
PMID: 27564267
High epitope-specific sensitivity of CD8(+) T cells is required for optimal immune protection against intracellular pathogens as well as certain malignancies. The quality of antigen recognition of CD8(+) T cells...
10.
Rucker-Braun E, Link C, Schmiedgen M, Tunger A, Vizjak P, Teipel R, et al.
Exp Hematol
. 2016 Jul;
44(11):1024-1033.e1.
PMID: 27473564
Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative treatment approach for patients with acute myeloid leukemia (AML) and chronic lymphocytic leukemia (CLL). Graft versus leukemia (GVL) effects, which are...